Skip to main content
. Author manuscript; available in PMC: 2016 Feb 11.
Published in final edited form as: J Immunol. 2014 Sep 3;193(7):3803–3815. doi: 10.4049/jimmunol.1400571

Figure 6. Pitavastatin inhibits allograft rejection via activation of endothelial ERK5.

Figure 6

After 2 weeks of 4-OHT injection, VE-Cad-CreER/WT or ERK5-EKO hearts were transplanted to the recipient abdominal aorta. The recipients were then orally administrated pitavastatin (3 mg/kg) or vehicle (sterilized distilled water) twice a day. To gauge the graft rejection, manual palpation was performed twice a day until the donor heart stops beating. (A) Kaplan-Meier plots indicate that pitavastatin prolongs VE-Cad-CreER/WT (left), but not ERK5-EKO (middle, right), allograft survival. (B) Five days after transplantation, relative mRNA expression levels of TNFα, IFNγ, MCP-1, IL-1, IL-6, and IL-10 in allografts were measured by qPCR and expressed relative to the GAPDH mRNA expression level. In each allograft group, values represent the ratio of mean value of pitavastatin-treated samples to mean value of vehicle treated samples. Values are mean±SD, n value as indicated in graphs. n.s: not significant.